On May 2, 2023 NKGen Biotech Inc. ("NKGen"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer ("NK") cell therapeutics, reported an upcoming presentation on its NK cell therapy (SNK01) at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 26th Annual Meeting, which will take place in Los Angeles, California from May 16 – 20, 2023 (Press release, NKGEN Biotech, MAY 2, 2023, View Source [SID1234630852]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Presentation Title: SNK01 Autologous Enhanced Natural Killer Cells and an Immune Checkpoint Inhibitor Control Tumor Growth in Rare Chemotherapy-Resistant Advanced Soft Tissue Sarcomas

Presenting Author: Erlinda M. Gordon, M.D.

Session Type: Poster Presentation

Date & Time: Thursday, May 18, 2023; 12:00 p.m. – 2:00 p.m. PT

Abstract Number: 1136

Dr. Gordon will present data from three rare cases of chemotherapy-resistant advanced soft tissue sarcomas (STS) which achieved durable partial responses and disease control with SNK01 plus an immune checkpoint inhibitor. NKGen believes the data from these three cases support the potential combination of SNK01 and an immune checkpoint inhibitor in controlling tumor growth with manageable toxicity.

Full abstracts are available on the ASGCT (Free ASGCT Whitepaper) conference website View Source